CD4+ T Cells Play a Critical Role in the Generation of Primary and Memory Antitumor Immune Responses Elicited by SA-4-1BBL and TAA-Based Vaccines in Mouse Tumor Models-Reference-Cited by-同舟云学术

CD4+ T Cells Play a Critical Role in the Generation of Primary and Memory Antitumor Immune Responses Elicited by SA-4-1BBL and TAA-Based Vaccines in Mouse Tumor Models

Published:2013-09-16 Issue:9 Volume:8 Page:e73145
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Sharma Rajesh K.,Yolcu Esma S.,Srivastava Abhishek K.,Shirwan Haval

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes;JA Keene;J Exp Med,1982

2. Defective CD8 T cell memory following acute infection without CD4 T cell help;JC Sun;Science,2003

3. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection;JC Sun;Nat Immunol,2004

4. Expanding roles for CD4(+) T cells in immunity to viruses;SL Swain;Nat Rev Immunol,2012

5. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype;D Hirschhorn-Cymerman;J Exp Med,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth;Vaccines;2024-03-21

2. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer;Cancer Immunology, Immunotherapy;2023-08-22

3. Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy;Journal of Controlled Release;2022-04

4. Infectious Bronchitis Virus (Gammacoronavirus) in Poultry Farming: Vaccination, Immune Response and Measures for Mitigation;Veterinary Sciences;2021-11-12

5. Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53;OncoImmunology;2020-01-01